Skip to main content
. 2017 Apr 20;8(32):52813–52822. doi: 10.18632/oncotarget.17264

Figure 3. Expression of VEGFR-2 in CNE-2 NPC tumor tissue from D0, D5, D10 and D15.

Figure 3

(A) Immunohistochemical staining of xenografted CNE-2 NPCs from D0, D5, D10 and D15 with an anti-VEGFR-2 antibody(x400 magnification). (B) VEGFR2 positivity (%) within D0, D5, D10 and D15 groups.* P < 0.05 vs. D0 group. * P >0.05 vs. D15 group.